News Recap: BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) stock identified change of 117.39% away from 52-week low price and recently located move of -67.60% off 52-week high price. It has market worth of $422.91M. BCRX stock has been recorded 0.42% away from 50 day moving average and -1.65% away from 200 day moving average. Moving closer, we can see that shares have been trading 6.83% off 20-day moving average.

On Feb. 25, 2020, BioCryst Pharmaceuticals (NASDAQ:BCRX) disclosed that the company has appointed former Pfizer chief financial officer (CFO), Alan G. Levin, to its board of directors (BOD).

In addition to his 20-year career at Pfizer, Mr. Levin served as CFO of Endo Pharmaceuticals over a five-year period where the company experienced a nearly 400 percent increase in its market capitalization.

He currently serves on the BOD of Diffusion Pharmaceuticals, a development stage company focused on therapeutics to enhance the effectiveness of treatments for stroke and cancer, and on the advisory board of Auven Therapeutics, a global private equity fund that acquires and pursues accelerated development of breakthrough therapeutic drugs, prior to licensing them to commercial partners.

From 2014 through 2019, Mr. Levin served on the BOD of Aceto Corporation, a multinational company involved in the sale and distribution of generic drugs, pharmaceutical intermediates and performance chemicals. He also serves on the BOD of the Critical Path Institute, a nonprofit collaboration between the U.S. Food and Drug Administration and the pharmaceutical industry, focused on streamlining and accelerating the development and regulatory pathways for innovative medicines.

With a significant therapy nearing approval this year, and a pipeline of home-grown oral medicines for rare diseases right behind it, BioCryst is transitioning into a commercial company positioned for long-term success delivering innovative medicines to patients. I look forward to adding my contribution to the outstanding board and management team, said Mr. Levin.

The Healthcare sector company, BioCryst Pharmaceuticals noticed change of 9.29% to $3 along volume of 10907560 shares in recent session compared to an average volume of 3.51M. The stock observed return of 17.65% in 5 days trading activity. The stock was at 2.39% over one month performance. BCRX’s shares are at 21.21% for the quarter and driving a -63.68% return over the course of the past year and is now at -13.04% since this point in 2018.

The average volatility for the week at 16.76% and for month was at 9.15%. There are 140.97M shares outstanding and 140.97M shares are floated in market. Right now the stock beta is 1.98.

John Gonzalez covers business and finance news. He is the only person we trust to provide breaking news in the finance category. Having already completed an Associates Degree in Psychology, John Gonzalez is now finishing his Bachelor’s degree in Communications. In preparation for working in the advertisement sector, John is writing financial content and analysis. On a daily basis, he works on articles regarding the following topics: business, top trends, technology, and politics.

Address: 7302 Benton Street, Arvada, CO 80003, USA


Zip Code: 80003

Phone Number: 303-420-7222

Leave a Reply

Your email address will not be published. Required fields are marked *